We provide you with 20 years of free, institutional-grade data for IDYA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IDYA. Explore the full financial landscape of IDYA stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Hata Yujiro S | Derivatives Exercise | 12,808 | 2025-02-19 | ||
| Throne Jason | Derivatives Exercise | 53,484 | 2024-06-27 | ||
| WHITE MICHAEL ANTHONY | Sale | -28,500 | $36.23 | $1,032,415 | 2024-05-31 |
| WHITE MICHAEL ANTHONY | Derivatives Exercise | 28,500 | 2024-05-31 | ||
| Hata Yujiro S | Sale | -175,000 | $41.6 | $7,280,193 | 2024-05-16 |
| Hata Yujiro S | Derivatives Exercise | 175,000 | 2024-05-16 | ||
| Ruiz Briseno Andres | Sale | -2,000 | $46.02 | $92,045 | 2024-02-13 |
| Hata Yujiro S | Sale | -99,372 | $45.15 | $4,486,368 | 2024-02-12 |
| Hata Yujiro S | Derivatives Exercise | 99,372 | 2024-02-12 | ||
| Hata Yujiro S | Sale | -628 | $45 | $28,260 | 2024-02-05 |
| Hata Yujiro S | Derivatives Exercise | 628 | 2024-02-05 | ||
| Ruiz Briseno Andres | Sale | -2,000 | $42.03 | $84,050 | 2024-01-24 |
| Ruiz Briseno Andres | Sale | -2,000 | $38.01 | $76,026 | 2024-01-17 |
| Hata Yujiro S | Sale | -75,000 | $40.04 | $3,002,895 | 2024-01-17 |
| Hata Yujiro S | Derivatives Exercise | 75,000 | 2024-01-17 | ||
| Hata Yujiro S | Sale | -75,000 | $35.03 | $2,627,618 | 2023-12-19 |
| Hata Yujiro S | Derivatives Exercise | 75,000 | 2023-12-19 | ||
| Throne Jason | Sale | -10,000 | $35.04 | $350,371 | 2023-12-19 |
| Throne Jason | Derivatives Exercise | 20,000 | 2023-12-19 | ||
| Ruiz Briseno Andres | Sale | -2,000 | $34 | $68,000 | 2023-12-18 |
| Throne Jason | Sale | -5,163 | $30.09 | $155,360 | 2023-11-07 |
| Throne Jason | Derivatives Exercise | 5,163 | 2023-11-07 | ||
| Throne Jason | Sale | -1,000 | $30 | $30,000 | 2023-09-14 |
| Throne Jason | Derivatives Exercise | 1,000 | 2023-09-14 | ||
| Ruiz Briseno Andres | Sale | -2,000 | $30.01 | $60,016 | 2023-09-06 |
| Throne Jason | Sale | -3,837 | $30.03 | $115,224 | 2023-09-06 |
| Throne Jason | Derivatives Exercise | 3,837 | 2023-09-06 | ||
| Stone Paul A. | Sale | -5,000 | $28.87 | $144,352 | 2023-08-31 |
| Stone Paul A. | Sale | -978 | $26.4 | $25,819 | 2023-08-23 |
| Stone Paul A. | Sale | -4,022 | $26.45 | $106,382 | 2023-08-18 |
| Throne Jason | Sale | -5,000 | $25.09 | $125,430 | 2023-08-11 |
| Throne Jason | Derivatives Exercise | 5,000 | 2023-08-11 | ||
| Stone Paul A. | Sale | -2,500 | $25.05 | $62,613 | 2023-08-11 |
| Throne Jason | Sale | -9,485 | $23 | $218,178 | 2023-07-12 |
| Throne Jason | Derivatives Exercise | 9,485 | 2023-07-12 | ||
| Ruiz Briseno Andres | Initial | 2023-07-03 | |||
| Throne Jason | Sale | -3,985 | $23 | $91,669 | 2023-06-02 |
| Throne Jason | Derivatives Exercise | 3,985 | 2023-06-02 | ||
| Throne Jason | Sale | -500 | $23 | $11,500 | 2023-05-24 |
| Throne Jason | Derivatives Exercise | 500 | 2023-05-24 | ||
| Stone Paul A. | Derivatives Exercise | 8,000 | 2023-04-14 | ||
| Hata Yujiro S | Derivatives Exercise | 11,601 | 2023-04-13 |
The information provided in this report about IDYA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
IDEAYA Biosciences, Inc(NASDAQ:IDYA) 
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is...
Website: http://www.ideayabio.com
Founded: 2015
IPO Price: $10 (May 23, 2019)
Full Time Employees: 58
CEO: Yujiro S. Hata
Sector: Healthcare
Industry: Biotechnology